Loading
A phase 3 trial of Tislelizumab, Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by BeiGene, active and no longer recruiting.
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma is a phase 3 interventional study registered as NCT03967977 by BeiGene, with 420 participants enrolled, started 2019-05-29 and due to reach its primary completion in 2027-06-30. Interventions recorded: Tislelizumab, Placebo, Cisplatin, Gemcitabine Hydrochloride and Carboplatin.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Platinum agents and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Platinum agents and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Platinum agents and the tag pipeline.